Cas No.Product NameDescription
879085-55-9Vismodegib Vismodegib is a more potent novel and specific synthetic oral hedgehog pathway inhibitor with an IC50 of 3 nM.
162635-04-3TemsirolimusTemsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
159351-69-6EverolimusEverolimus (RAD001) also known as SDZ-RAD, Certican, Zortress, Afinitorm is MTOR inhibitor with IC50 of 0.63 nM.
475110-96-4ZSTK474ZSTK474 is an inhibitor of PI3K γ (IC50 at 6 nM
900515-16-4AS252424AS-252424 is a furan-2-ylmethylene thiazolidinedione as a selective ATP-competitive PI3Kγ inhibitor with IC50 with 33 nM.
677338-12-4PIK-90PIK-90 is a PI3K inhibitor,IC50=11, 350, 18, and 58 for p110 α, β, γ and δ isoforms.
371242-69-2IC-87114IC-87114 was the first isoform-selective PI3K inhibitor.
900185-02-6PIK-294PIK-294 displays selectivity with respect to the inhibition of PI3K isoforms p110β, p110δ, and p110γ, however it is most selective for PI3Kδ (IC 50 = 490, 10, and 160 nM, respectively).
1197160-78-3PF-05212384PKI-587 is a highly potent dual PI3K/mTOR kinase inhibitor with IC50 of 0.4 nM and <0.1 μM for PI3K-α and mTOR, respectively.
648450-29-7AS-605240AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM).
1009298-09-2AZD8055AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
1144068-46-1WYE-125132WYE-125132 is a highly potent, ATP-competitive and specific mTOR kinase inhibitor with an IC50 of 0.19 nM.
1173900-33-8AZD-6482AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor (IC(50) 0.01 μm). AZD6482 inhibited insulin-induced human adipocyte glucose uptake in vitro (IC(50) of 4.4 μm).
1349796-36-6Voxtalisib AnalogueXL765 is a mixed mTOR/PI3k inhibitor with IC50 of 157, 39, 113, 9 and 43 nM for mTOR, p110α, β, γ and δ, respectively.
1092351-67-1PP242PP 242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM.
677297-51-7TG100-115TG100-115 inhibits PI3Kγ and -δ, with IC50 of 83 and 235 nM, respectively. TG100-115 is not active for PI3Kα and -β, with IC50 of 1.2 and 1.3 mM. TG100-115 (10 μM) interrupts other VEGF signaling pathways, such as those that culminate in VE-cadherin phosphorylation.
944396-07-0BKM120Buparlisib, also known as BKM120, is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity.
601514-19-6TWS119TWS119 is inhibitor of glycogen synthase kinase-3β (IC50 = 30 nM).
1258861-20-9LY2940680LY2940680 is a potent agent used to treat cancer.
870281-82-6CAL-101CAL-101 is a potent PI3K p110δ inhibitor with an IC50 of 65 nM.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway